Compare
IB Acquisition Corp. vs NRC Health vs Medpace Holdings, Inc. vs Incyte Corp
| Latest fiscal year | IB Acquisition Corp. IBAC | NRC Health NRC | Medpace Holdings, Inc. MEDP | Incyte Corp INCY |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $137.39M | $2.53B | $5.14B |
| Revenue growth (YoY) | n/a | -4.0% | +20.0% | +21.2% |
| Gross margin | n/a | n/a | n/a | 92.8% (computed) |
| Operating margin | n/a | 16.4% | 21.1% | 29.5% |
| Net margin | n/a | 8.4% | 17.8% | 25.0% |
| Net income | $3.42M | $11.60M | $451.12M | $1.29B |
| EPS (Diluted) | n/a | $50.00 | $15.28 | $6.41 |
| Operating cash flow | -$1.32M | $26.45M | $713.22M | $1.41B |
| Free cash flow | n/a | $15.74M | $681.87M | n/a |
| Cash & equivalents | $428.7K | $4.14M | $497.05M | $3.10B |
| Total assets | $17.13M | $134.88M | $1.98B | $6.96B |
| Total liabilities | $1.83M | $120.89M | $1.52B | $1.79B |
| Shareholders' equity | -$681.3K | $13.99M | $459.07M | $5.17B |
| Return on year-end equity | n/a | 82.9% | 98.3% | 24.9% |
| Shares outstanding | 4.25M | 22.64M | 28.37M | 198.46M |
Revenue, most recent five fiscal years
| Fiscal year | IB Acquisition Corp. | NRC Health | Medpace Holdings, Inc. | Incyte Corp |
|---|---|---|---|---|
| Latest | n/a | $137.39M Ended 2025-12-31 | $2.53B Ended 2025-12-31 | $5.14B Ended 2025-12-31 |
| 1 year earlier | n/a | $143.06M Ended 2024-12-31 | $2.11B Ended 2024-12-31 | $4.24B Ended 2024-12-31 |
| 2 years earlier | n/a | $148.58M Ended 2023-12-31 | $1.89B Ended 2023-12-31 | $3.70B Ended 2023-12-31 |
| 3 years earlier | n/a | $151.57M Ended 2022-12-31 | $1.46B Ended 2022-12-31 | $3.39B Ended 2022-12-31 |
| 4 years earlier | n/a | $147.95M Ended 2021-12-31 | $1.14B Ended 2021-12-31 | $2.99B Ended 2021-12-31 |